A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Fulvestrant (Primary) ; Goserelin (Primary) ; Lerociclib (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors EQRx
- 05 Dec 2023 Status changed from active, no longer recruiting to discontinued based on corporate changes at EQRx. The discontinuation is not because of any efficacy or safety issues with lerociclib.
- 04 Oct 2023 The trial has been discontinued in Belgium, according to European Clinical Trials Database record.
- 20 Jul 2023 Status changed from recruiting to active, no longer recruiting.